[e-drug] Use of ceftriaxone in poor countries (6)

E-DRUG: Use of ceftriaxone in poor countries (6)
-------------------------------------------

Dear All,

I agree with Christian as we all know that quality is the issue in generic counterparts of some therapeutic classes.

Sales of Roche's world leading injectable antibiotic Ceftriaxone exceeded US$1 billion in 2003 and 2004; faced with generic competition in 2005, sales of the branded product declined US$746 million. Lupin was first to achieve FDA ANDA approval for its generic version of ceftriaxone, followed by Sandoz, Orchid and Baxter.

A couple of studies showing differences in response to originator and generic copies:

Lambert PA and Conway BR. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J Chemother 2003 Aug;15(4):357-68

Schito GC, Keenan MH. Predicting the clinical efficacy of generic formulations of ceftriaxone. J Chemother. 2005 Sep;17 Suppl 2:33-40

Shazia Jamshed
PhD Scholar
Social and Administrative Pharmacy
School of Pharmaceutical Sciences
Universiti Sains Malaysia
Penang
Malaysia
Core Member Medicine Pakistan International
E-mail: shazia_12@yahoo.com
http://medicinespakistan.org/projects/